# Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis with Translocation (11;14)

> **NCT05996406** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Peking Union Medical College Hospital** · enrollment: 36 (estimated)

## Conditions studied

- Light Chain (AL) Amyloidosis
- CCND1 Translocation
- Venetoclax

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Dexamethasone Oral

## Key facts

- **NCT ID:** NCT05996406
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-07
- **Primary completion:** 2024-11-13
- **Final completion:** 2025-09
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2025-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05996406

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05996406, "Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis with Translocation (11;14)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05996406. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*